NCT07632157Not yet recruitingPhase 3
MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation
MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation (MAGNETIC-AF)
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
The purpose of this research study is to find out if the use of magnesium in addition to Metoprolol, a rate controlling medication that you would be offered in the Emergency Department today unrelated to this study, will help reduce your high heart rate (rapid ventricular response).
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 196 (estimated)
- First submitted
- 21 May 2026
- Start date
- Oct 2026
- Primary completion date
- Dec 2028
- Lead sponsor
- Wake Forest University Health Sciences
- Diseases
- Atrial fibrillation
- NCT number
- NCT07632157
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 196
- From Oct 2026 to the primary completion date, Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously enrolled in this trial during a different patient encounter
Other illness
- Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging
- Rhythms other than atrial fibrillation, such as sick sinus syndrome or wide-complex ventricular response
- Acute myocardial infarction
- Allergy or sensitivity to any study drugs
Lab values
- Contraindications to magnesium sulfate (including myasthenia gravis)
Other
- Hemodynamically unstable patients (SBP \<90, MAP \<65)
- Impaired consciousness
- Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis
- Withdrew from study
Who the study is looking for
- Age \> 18 years or older
- Able to provide informed consent
- Primary diagnosis atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR) greater than or equal to 120 beats per minute
- Metoprolol as rate control agent
- English speaking
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Advocate Christ Medical Center Emergency Department (ACMC ED) Coordinator of this site? Confirm its status | Oak Lawn | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.